Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.

Abstract: Undesired mast cell activities are linked with various diseases or disorders, such as allergies, inflammatory diseases, autoimmune diseases, and cancers. There remains a need for new and improved therapeutics (e.g., for mast cell associated diseases or disorders) that can target c-Kit and/or siglec-6. Disclosed herein are molecules, such as antibodies and antibody fragments, capable of binding to c-Kit and/or siglec-6.

Abstract: Provided herein are single-chain and multi-chain chimeric antigen receptors, nucleic acids encoding the same, and mammalian cells expressing the same. Also provided are methods of treating a cancer in a subject using a mammalian cell expressing any of these single-chain and multi-chain chimeric antigen receptors.

Abstract: Disclosed herein are methods of treating autoimmune, allergic, and/or inflammatory diseases in a subject in need thereof, comprising administering a therapeutic agent comprising one or more antigen-binding sites on a cell involved in the autoimmune, allergic, and/or inflammatory diseases and depleting the cell.

Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

Abstract: The methods and compositions disclosed herein relate to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through improvement of the tumor microenvironment via improvement in cytokine signaling. Methods of treating a cancer in a patient are disclosed comprising administering to the patient immune cells expressing a chimeric antigen receptor or T-cell receptor and a membrane bound IL-18. Further disclosed are nucleic acids which encode a membrane bound IL-18 and methods for culturing cells expressing such nucleic acids.

Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.

Abstract: Provided herein are chimeric transmembrane proteins, nucleic acids encoding these chimeric transmembrane proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.

Abstract: The present invention relates to methods and compositions for reducing the immunogenicity of chimeric Notch receptors, and specifically to transcription factors useful for controlling gene expression delivered to tissues by such chimeric Notch receptors.

Abstract: Provided herein are chimeric transmembrane proteins, nucleic acids encoding these chimeric transmembrane proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.

Abstract: Provided herein are engineered receptors that include an extracellular domain (ECD) from a TGF-? receptor, a transmembrane domain (TMD), and that lack amino acid residues for signaling and phosphorylation, where such receptors are involved in cytokine signaling, for modulating TGF-? signaling, for methods of modulating TGF-? signaling, and for treating cancer using chimeric antigen receptors.

Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.

Abstract: Provided herein are engineered receptors involved in cytokine signaling. Also provided herein are engineered receptors for modulating TGF-? signaling, methods of modulating TGF-? signaling and treating cancer using chimeric antigen receptors.

Abstract: Provided herein are chimeric antigen receptors that binds specifically to B-cell maturation antigen (BCMA) and CD307e, nucleic acids that encode these chimeric antigen receptors, and methods of making and using these chimeric antigen receptors.

Abstract: Disclosed herein are polynucleotides encoding cell tags for use in immunotherapeutic applications, and systems comprising polynucleotide cell tags for regulating the activity of a cell. The compositions, methods and systems described herein provide tools for regulating activity of genetically engineered cells in a subject.

Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

Abstract: Methods and compositions are provided for reversibly localizing proteins to the exterior part of the cell surface. Compositions provided herein can include nucleic acids that encode polypeptides of interest and the ligand binding domain (LBD) of a nuclear hormone receptor. Medical applications are provided, including controlling the toxicity of CAR T cells.

Abstract: Provided herein are chimeric transmembrane proteins and proteins, nucleic acids encoding these chimeric transmembrane proteins or proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.

Abstract: Provided herein are chimeric antigen receptors (CARs) for cancer therapy, and more particularly, CARs containing a scFv from a CD33 monoclonal antibody. Provided are immune effector cells containing such CARs, and methods of treating proliferative disorders such as acute myeloid leukemia (AML), and relapsed or refractory AML.

Abstract: Provided herein are chimeric transmembrane proteins and proteins, nucleic acids encoding these chimeric transmembrane proteins or proteins, and mammalian cells containing these nucleic acids, and methods of making and using these mammalian cells.